The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

Lo.Li.Pharma

Status: Suspended

Conditions: Metabolic Syndrome; Cardiac Fibrosis

Treatments: Dietary Supplement: Inositol and alpha-lactalbumin

Study type: Interventional

Funder types: Industry

Identifiers

NCT05689710

CARDIO_INO22

Details and patient eligibility

About

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

Enrollment: 30 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

At least 3 of the following inclusion criteria:

• triglycerides levels ≥ 150 mg/dL
• HDL ≤ 40 mg/dL
• Fasting glycemia > 100 mg/dL <126 mg/dl
• Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg
• Hip circumference > 102 cm in men or 88 cm in women

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

30 participants in 2 patient groups

No intervention

No Intervention group

Experimental

Experimental group

Description:

Dietary Supplement with inositols and alpha-lactalbumin

Treatment:

Dietary Supplement: Inositol and alpha-lactalbumin